Haleon PLC Sponsored ADR (NYSE:HLN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company.

Several brokerages have recently weighed in on HLN. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research note on Wednesday, September 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th.

Haleon Stock Down 0.7%

Shares of NYSE:HLN opened at $9.01 on Monday. The company has a market capitalization of $39.62 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 2.05 and a beta of 0.12. The company has a 50 day moving average of $9.69 and a two-hundred day moving average of $9.57. Haleon has a 52-week low of $8.65 and a 52-week high of $11.28. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38.

Haleon Cuts Dividend

The firm also recently declared a dividend, which was paid on Thursday, September 17th. Investors of record on Friday, August 14th were paid a $0.0642 dividend. This represents a dividend yield of 132.0%. This is a negative change from Haleon’s previous dividend of $0.1307. The ex-dividend date was Friday, August 14th. Haleon’s payout ratio is presently 30.77%.

Institutional Investors Weigh In On Haleon

Hedge funds have recently bought and sold shares of the business. QRG Capital Management Inc. raised its position in shares of Haleon by 1.1% in the 2nd quarter. QRG Capital Management Inc. now owns 383,552 shares of the company’s stock valued at $3,579,000 after purchasing an additional 4,035 shares in the last quarter. Altar Rock LLC purchased a new position in shares of Haleon during the 2nd quarter valued at approximately $132,000. WINTON GROUP Ltd acquired a new stake in shares of Haleon during the second quarter worth approximately $494,000. Engineers Gate Manager LP acquired a new stake in shares of Haleon during the second quarter worth approximately $1,869,000. Finally, NorthRock Partners LLC increased its stake in shares of Haleon by 31.5% in the second quarter. NorthRock Partners LLC now owns 52,244 shares of the company’s stock worth $487,000 after buying an additional 12,500 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.